Prosecution Insights
Prosecution Insights
Technology area: Medical Devices & Mechanical Engineering
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Verve Medical Inc. holds a patent portfolio in the Medical Devices & Mechanical Engineering technology area. The company currently has 1 pending office action. This workload is managed by 1 distinct examiner and is situated within 1 distinct art unit. These figures indicate that the company's current patent activity is focused on a single technical area and a single point of review. The portfolio does not show a broad distribution of cases across the patent office. This focus allows for a more concentrated effort in securing intellectual property for its medical technologies.
The busiest examiner for Verve Medical Inc. is ZINK, AMANDA L, who is responsible for 1 pending office action. This examiner has 1 busiest examiner pending case, which is the only pending action for the company. This means that ZINK, AMANDA L is the sole official currently evaluating the company's patent claims. The presence of 1 distinct art unit suggests that the technical merits of the filing are being assessed by 1 specialized group. This concentration allows for a unified prosecution strategy but also means the company's immediate success is tied to the specific review of this 1 examiner. The focus on 1 distinct examiner simplifies the management of the current prosecution pipeline and allows for highly tailored legal arguments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZINK, AMANDA L | 1 | 85.2% | +3.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18374601 | Treatment of Kidney Disease Using Renal Nerve Denervation Via the Renal Pelvis | ZINK, AMANDA L | — |
| Art Unit | Apps |
|---|---|
| 3794 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18374601 | Treatment of Kidney Disease Using Renal Nerve Denervation Via the Renal Pelvis | ZINK, AMANDA L | 3794 | §102§103 | Non-Final OA | — | Pending | Sep 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial